News Headlines

1. Asimov Launches RNA Edge, A Lab-In-The-Loop Platform For AI Optimization Of RNA Therapeutic Candidates 3/19/2026

   Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, announces the launch of its RNA Edge System, an integrated AI, synthetic biology, and laboratory platform to optimize RNA therapies.

2. Pyramid Pharma Services Signs Commercial Agreement With A Top 3 Global Pharma Innovator To Support siRNA Injectable Therapy 3/19/2026

   Pyramid Pharma Services, a U.S.-based contract development and manufacturing organization (CDMO) specializing in sterile fill-finish manufacturing and integrated drug product services—including device assembly, labeling, and packaging—for injectable therapies, today announced that it has entered into a five-year commercial supply agreement with a leading global pharmaceutical company to support the commercial manufacture of a small interferon RNA (siRNA) injectable therapy used to treat a rare genetic kidney disease.

3. Trinity Biotech Announces Collaboration With University At Buffalo To Commercialize Novel Biomarkers For Sjögren's Syndrome 3/18/2026

   Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York (“UB”). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren’s Syndrome, one of the most common but underdiagnosed autoimmune diseases.

4. Abzena Recognized As A Market-Leading Antibody-Drug Conjugate CDMO In Frost & Sullivan Radar Report 3/18/2026

   Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced it has been named a leader in the Frost Radar™ Report for Antibody Drug Conjugate Contract Development and Manufacturing Organizations.

5. Taiwan Bio Partners With Terumo Blood And Cell Technologies To Advance Automated Treg Manufacturing On Quantum Flex 3/18/2026

   Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, has entered into a collaboration with Taiwan Bio Therapeutics Inc. (Taiwan Bio) to transition regulatory T-cell (Treg) manufacturing onto the automated Quantum Flex platform, supporting a move from manual processes toward more scalable, repeatable production.

6. Viral Vector Manufacturing (VVMF) Enters Into Licensing Agreement With OXB, Gaining Access To The OXB AAV And LV Viral Vector Platforms 3/18/2026

   Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a licensing and option agreement with OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO.

7. New England Biolabs® Releases EnClose™ Cell-Free dbDNA™ Synthesis Kit In Collaboration With Touchlight To Accelerate DNA And RNA Therapeutic Development 3/18/2026

   New England Biolabs (NEB®) today announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight.

8. BioCina Initiates Comprehensive Manufacturing Program For Patrys' Proprietary Injectable Therapeutic To Alleviate Delirium 3/17/2026

   BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.

9. Alebund Pharmaceuticals Announces Collaboration And License Agreement With R1 Therapeutics For AP306 3/17/2026

   Alebund Pharmaceuticals ("Alebund" or the "Company"), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the "Agreements") with R1 Therapeutics, Inc. ("R1"). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M.

10. Celltrion Signs Supply Agreement With A Global Biopharma Worth Up To KRW 375.4 Billion, Reflecting Recognition Of Product Quality And Manufacturing Productivity, And Accelerating CDMO Growth 3/17/2026

    Celltrion announced today that it has signed a contract manufacturing (CMO) agreement with a global pharmaceutical company for the supply of drug substance. The counterparty remains undisclosed to ensure business confidentiality.